MGMT methylation pattern of long-term and short-term survivors of glioblastoma reveals CpGs of the enhancer region to be of high prognostic value

MGMT methylation pattern of long-term and short-term survivors of glioblastoma reveals CpGs of the enhancer region to be of high prognostic value

Abstract Treatment with the alkylating agent temozolomide is known to be prognostically beneficial in a subset of glioblastoma patients. Response to such chemotherapeutic treatment and the prognostic benefit have been linked to the methylation status of O 6 -methylguanine-DNA methyltransferase (MGMT...

Full description

Bibliographic Details
Main Authors: Henning Leske, Ulrike Camenisch Gross, Silvia Hofer, Marian Christoph Neidert, Sabine Leske, Michael Weller, Dirk Lehnick, Elisabeth Jane Rushing
Format: Article
Language:English
Published: BMC 2023-08-01
Series:Acta Neuropathologica Communications
Subjects:
Glioblastoma
MGMT
Survival
Enhancer
Prognosis
Temozolomide
Online Access:https://doi.org/10.1186/s40478-023-01622-w

Similar Items

Similar Items